Cystic Fibrosis Forecast and Market Analysis to 2025

Cystic Fibrosis Forecast and Market Analysis to 2025

  • September 2018 •
  • 336 pages •
  • Report ID: 5779843 •
  • Format: PDF
Disease Overview
Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications. The prognosis of patients has improved markedly over recent decades with the advent of new treatments, increasing the mean life expectancy of patients to 37 years. These include inhaled antibiotics for managing chronic lung infections, as well as mucolytics that facilitate the breakdown and clearance of mucus from the lungs, improving airflow and decreasing the risk of infection.

Recent events and opinion

Vertex is building a durable $7bn portfolio of CFTR modulators.
Uptake of latest wave of therapies will uphold improvements in prognosis and life expectancy seen in recent decades.
Prevalent cases are expected to increase over the forecast period mainly due to improving survival rates.
Vertex’s dominance of the cystic fibrosis market is set to continue.
Triple combination therapies with Kalydeco-like efficacy and broad label coverage set foundation for blockbuster status.